AROG ARO 021 Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated AML

September 14, 2018
https://clinicaltrials.gov/ct2/show/NCT03258931
Cancer - Leukemia
Principal Investigator: Yue Guo, MD
leukemia, FLT3, myeloid
Accepting Participants